Artiva Biotherapeutics (ARTV) Competitors $2.88 +0.11 (+3.97%) Closing price 04:00 PM EasternExtended Trading$2.88 +0.00 (+0.17%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ARTV vs. DBVT, AVIR, SGMT, ADCT, IMMP, GALT, VOR, FDMT, AARD, and ANNXShould you be buying Artiva Biotherapeutics stock or one of its competitors? The main competitors of Artiva Biotherapeutics include DBV Technologies (DBVT), Atea Pharmaceuticals (AVIR), Sagimet Biosciences (SGMT), ADC Therapeutics (ADCT), Prima BioMed (IMMP), Galectin Therapeutics (GALT), Vor Biopharma (VOR), 4D Molecular Therapeutics (FDMT), Aardvark Therapeutics (AARD), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry. Artiva Biotherapeutics vs. Its Competitors DBV Technologies Atea Pharmaceuticals Sagimet Biosciences ADC Therapeutics Prima BioMed Galectin Therapeutics Vor Biopharma 4D Molecular Therapeutics Aardvark Therapeutics Annexon DBV Technologies (NASDAQ:DBVT) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk. Which has higher earnings and valuation, DBVT or ARTV? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDBV TechnologiesN/AN/A-$113.92M-$4.77-2.10Artiva BiotherapeuticsN/AN/A-$65.37MN/AN/A Is DBVT or ARTV more profitable? Artiva Biotherapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -3,220.49%. Artiva Biotherapeutics' return on equity of -42.60% beat DBV Technologies' return on equity.Company Net Margins Return on Equity Return on Assets DBV Technologies-3,220.49% -287.15% -138.83% Artiva Biotherapeutics N/A -42.60%-37.76% Do analysts rate DBVT or ARTV? DBV Technologies presently has a consensus price target of $14.75, indicating a potential upside of 47.50%. Artiva Biotherapeutics has a consensus price target of $17.00, indicating a potential upside of 490.28%. Given Artiva Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Artiva Biotherapeutics is more favorable than DBV Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DBV Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in DBVT or ARTV? 71.7% of DBV Technologies shares are held by institutional investors. 1.4% of DBV Technologies shares are held by insiders. Comparatively, 21.4% of Artiva Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media refer more to DBVT or ARTV? In the previous week, DBV Technologies and DBV Technologies both had 2 articles in the media. DBV Technologies' average media sentiment score of 0.67 beat Artiva Biotherapeutics' score of -0.12 indicating that DBV Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Artiva Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryArtiva Biotherapeutics beats DBV Technologies on 8 of the 11 factors compared between the two stocks. Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTV vs. The Competition Export to ExcelMetricArtiva BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.35M$3.09B$5.83B$9.73BDividend YieldN/A2.23%3.84%4.09%P/E RatioN/A21.1631.1625.99Price / SalesN/A396.94474.86122.97Price / CashN/A43.0937.1558.38Price / Book0.478.069.116.38Net Income-$65.37M-$54.72M$3.26B$265.56M7 Day Performance4.73%2.52%2.06%1.89%1 Month Performance11.63%7.54%5.08%1.23%1 Year Performance-71.11%13.01%31.26%21.10% Artiva Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTVArtiva Biotherapeutics2.8392 of 5 stars$2.88+4.0%$17.00+490.3%-72.5%$70.35MN/A0.0081DBVTDBV Technologies3.3765 of 5 stars$9.57-2.6%$14.75+54.2%+105.5%$268.97M$4.15M-2.0180Gap UpAVIRAtea Pharmaceuticals1.793 of 5 stars$3.51+3.8%$6.00+70.9%-7.6%$268.23MN/A-2.1870SGMTSagimet Biosciences3.2654 of 5 stars$8.75+0.2%$26.57+203.7%+138.6%$267.79M$2M-4.978ADCTADC Therapeutics2.1782 of 5 stars$2.68-0.2%$7.75+189.7%+5.4%$265.80M$70.84M-1.84310IMMPPrima BioMed1.1536 of 5 stars$1.70-5.0%$7.00+311.8%-30.2%$262.75M$5.14M0.002,021Upcoming EarningsGALTGalectin Therapeutics2.4557 of 5 stars$3.88-6.5%$6.00+54.6%+66.5%$262.66MN/A-5.399VORVor Biopharma0.3541 of 5 stars$1.99-3.9%N/AN/A$262.14MN/A-1.32140Short Interest ↑FDMT4D Molecular Therapeutics2.1259 of 5 stars$5.53-1.8%$29.56+434.5%-54.9%$260.81M$40K-1.74120AARDAardvark TherapeuticsN/A$11.15-7.0%$33.00+196.0%N/A$260.13MN/A0.0018News CoverageAnalyst RevisionANNXAnnexon2.9439 of 5 stars$2.35-0.4%$12.50+431.9%-63.3%$258.93MN/A-1.9960 Related Companies and Tools Related Companies DBVT Alternatives AVIR Alternatives SGMT Alternatives ADCT Alternatives IMMP Alternatives GALT Alternatives VOR Alternatives FDMT Alternatives AARD Alternatives ANNX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTV) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access